Search

Your search keyword '"Wang, Joshua W."' showing total 21 results
Start Over Author "Wang, Joshua W."
21 results on '"Wang, Joshua W."'

7. Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease

Author

Peng, Shiwen, primary, Qiu, Jin, additional, Yang, Andrew, additional, Yang, Benjamin, additional, Jeang, Jessica, additional, Wang, Joshua W., additional, Chang, Yung-Nien, additional, Brayton, Cory, additional, Roden, Richard B. S., additional, Hung, Chien-Fu, additional, and Wu, T.-C., additional

Published
2016
Full Text
View/download PDF

10. Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies

Author

Wang, Joshua W., primary, Jagu, Subhashini, additional, Wu, Wai-Hong, additional, Viscidi, Raphael P., additional, Macgregor-Das, Anne, additional, Fogel, Jessica M., additional, Kwak, Kihyuck, additional, Daayana, Sai, additional, Kitchener, Henry, additional, Stern, Peter L., additional, Gravitt, Patti E., additional, Trimble, Cornelia L., additional, and Roden, Richard B. S., additional

Published
2015
Full Text
View/download PDF

13. Measurement of Neutralizing Serum Antibodies of Patients Vaccinated with Human Papillomavirus L1 or L2-Based Immunogens Using Furin-Cleaved HPV Pseudovirions

Author

Wang, Joshua W., primary, Jagu, Subhashini, additional, Wang, Chenguang, additional, Kitchener, Henry C., additional, Daayana, Sai, additional, Stern, Peter L., additional, Pang, Susana, additional, Day, Patricia M., additional, Huh, Warner K., additional, and Roden, Richard B. S., additional

Published
2014
Full Text
View/download PDF

18. A bis-Benzylidine Piperidone Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 as a Therapy for Cancer

Author

Anchoori, Ravi K., primary, Karanam, Balasubramanyam, additional, Peng, Shiwen, additional, Wang, Joshua W., additional, Jiang, Rosie, additional, Tanno, Toshihiko, additional, Orlowski, Robert Z., additional, Matsui, William, additional, Zhao, Ming, additional, Rudek, Michelle A., additional, Hung, Chien-fu, additional, Chen, Xiang, additional, Walters, Kylie J., additional, and Roden, Richard B.S., additional

Published
2013
Full Text
View/download PDF

21. Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease.

Author

Shiwen Peng, Andrew Yang, Benjamin Yang, Jessica Jeang, Wang, Joshua W., Yung-Nien Chang, Jin Qiu, Brayton, Cory, Roden, Richard B. S., Chien-Fu Hung, and Wu, T.-C.

Subjects
PAPILLOMAVIRUSES, DNA, DISEASE risk factors
Abstract

Background: Human papillomavirus (HPV) has been identified as the primary etiologic factor of cervical cancer as well as subsets of anogenital and oropharyngeal cancers. The two HPV viral oncoproteins, E6 and E7, are uniquely and consistently expressed in all HPV infected cells and are therefore promising targets for therapeutic vaccination. Both recombinant naked DNA and protein-based HPV vaccines have been demonstrated to elicit HPV-specific CD8+ T cell responses that provide therapeutic effects against HPV-associated tumor models. Here we examine the immunogenicity in a preclinical model of priming with HPV DNA vaccine followed by boosting with filterable aggregates of HPV 16 L2E6E7 fusion protein (TA-CIN). Results: We observed that priming twice with an HPV DNA vaccine followed by a single TA-CIN booster immunization generated the strongest antigen-specific CD8+ T cell response compared to other prime-boost combinations tested in C57BL/6 mice, whether naïve or bearing the HPV16 E6/E7 transformed syngeneic tumor model, TC-1. We showed that the magnitude of antigen-specific CD8+ T cell response generated by the DNA vaccine prime, TA-CIN protein vaccine boost combinatorial strategy is dependent on the dose of TA-CIN protein vaccine. In addition, we found that a single booster immunization comprising intradermal or intramuscular administration of TA-CIN after priming twice with an HPV DNA vaccine generated a comparable boost to E7-specific CD8+ T cell responses. We also demonstrated that the immune responses elicited by the DNA vaccine prime, TA-CIN protein vaccine boost strategy translate into potent prophylactic and therapeutic antitumor effects. Finally, as seen for repeat TA-CIN protein vaccination, we showed that the heterologous DNA prime and protein boost vaccination strategy is well tolerated by mice. Conclusions: Our results provide rationale for future clinical testing of HPV DNA vaccine prime, TA-CIN protein vaccine boost immunization regimen for the control of HPV-associated diseases. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results